Home > Boards > US Listed > Biotechs >

Amarin Corp. PLC ADS (AMRN)

AMRN RSS Feed
Add AMRN Price Alert      Hide Sticky   Hide Intro
Moderator: Dancing in the dark, rafunrafun, marzan, couldbebetter, everyonesguess, CalMustang
Search This Board: 
Last Post: 4/3/2020 2:02:15 PM - Followers: 955 - Board type: Free - Posts Today: 348

AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote 
Y! Finance AMRN Landing Page 
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page


VASCEPA RELATED LINKS & Outside Organizational News
The EPA Drug Initiative (EPADI)
Vascepa Savings Card Program
FDA Orange Book entry for Vascepa
Vascepa Prescribing Information
Vascepa Marine DTC Patient Brochure
Nissui EPA Synthesis History & Methodology
FDA Approval of Vascepa for the Reduction of Triglyceride Levels ≥ 500mg/dL (26 Jul 2012)
Pure EPA Vascepa Now Available in Half-Gram Capsule Size (25 Oct 2016)
ADA’s 2019 Standards of Medical Care in Diabetes Incorporate Findings from REDUCE-IT (28 Mar 2019)
New 2019 Updates to the European Society of Cardiology and European Atherosclerosis Society’s Guidelines incorporate Reduce-IT (3 Sep 2019)
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl (16 Sep 2019)
Independent Drug-Pricing Assessment Finds Vascepa Cost-Effective (17 Oct 2019)

RELEVANT SOCIAL MEDIA ACCOUNTS
Amarin Instagram - @amarincorp Amarin Twitter - @amarincorp Amarin LinkedIn Amarin ADP Portal - Job Openings Dr. Bhatt Twitter - @DLBHATTMD
TerraPharma Twitter - @TerraPharma1 John Cappello Twitter - @JohnCappello RafunRafun Twitter - @ra_fun K Trivedi Twitter - @GPUWorld  
 

VASCEPA CLINICAL TRIALS + FDA Meetings
Marine & Anchor (Amarin Led)
MARINE Study meets primary endpoints(29 Nov 2010)
ANCHOR Trial meets all Primary and Secondary Endpoints (18 Apr 2011)
Additional Inflammatory Marker Data from Marine and Anchor (22 Jan 2013)
New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in Marine and Anchor (8 April 2013)
FDA AD-Com Outcome for Anchor sNDA (16 October 2013)
FDA delays ANCHOR sNDA (20 Dec 2013)
Presentation of MARINE and ANCHOR analyses at AHA showing significant reduction of remnant-like particle cholesterol (17 Nov 2014)
Marine & Anchor Key Summaries (2017)
Vascepa showed reductions in potentially atherogenic lipids and inflammatory markers – Anchor post-hoc (12 Mar 2018)

REDUCE-IT (Amarin Led)
NIH Clinical Trial Page
Amarin Announces Dosing of First Patient in REDUCE-IT (7 Dec 2011)
Amarin and FDA Reaffirm Concurrence on REDUCE-IT through SPA Agreement Amendment (4 Aug 2016)
Amarin Randomizes Final Patient into REDUCE-IT (31 Aug 2016)
REDUCE-IT to Continue As Planned at Recommendation of Independent Data Monitoring Committee (14 Aug 2017)
REDUCE-IT Meets Primary Endpoint (24 Sep 2018)
REDUCE-IT Displayed 25% RRR in 5-Point MACE (10 Nov 2018)
REDUCE-IT NEJM Article(3 Jan 2019)
REDUCE-IT showed 30% reduction in total Cardiovascular events (18 Mar 2019)
Amarin submits sNDA seeking new indication based on REDUCE-IT (28 Mar 2019)
FDA Grants Priority Review for Vascepa sNDA (29 May 2019)
Amarin Notified of Ad-Com Meeting Planned for Nov 2019 (8 Aug 2019)
REDUCE-IT USA-specific Results released (11 Nov 2019)
FDA AD-Com Outcome for REDUCE-IT sNDA (14 Nov 2019)
REDUCE-IT related data presented at 2019 AHA (18 Nov 2019)

Law Suits
Amarin Granted Summary Judgement against FDA seeking NCE market exclusivity (28 May 2015)
First Amendment Decision a win for Amarin & Physician Plaintiffs (7 Aug 2015)
Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation (9 Mar 2016)
Amarin announces patent litigation settlement agreement with TEVA (24 May 2018)
Section Pending

PARTNERSHIPS / OVERSEAS
Amarin and Eddingpharm announce agreement for Vascepa in China (26 Feb 2015)
Amarin and HLS announce agreement for Vascepa in Canada (25 Sep 2017)
Commencement of Vascepa Clinical Development in China (17 Jan 2018)
Biologix and Amarin announce approval of Vascepa in Lebanon for patients with Triglyceride Levels ≥ 500mg/dL (21 Mar 2018)
Amarin & Mochida Announce Collaboration on Future Development of EPA-Based Drug Products and Indications (12 Jun 2018)
Biologix and Amarin announce approval of Vascepa in UAE for patients with Triglyceride Levels ≥ 500mg/dL (26 Jul 2018)
Vascepa granted Priority Review from Health Canada New Drug Submission, anticipated to be filed in April 2019 by HLS (29 Mar 2019)
HLS files New Drug Submission for Vascepa with Health Canada (29 April 2019)

PATENTS
Amarin list of Patents on Justia (h/t @Terrapharma1)

EPA Trials for other indications
Section Pending

Non-Vascepa (AMR-101) Amarin Trials
Section Pending

 

AMRN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMRN News: ALYI Trending VERY BULLISH at $0.004 with 1000% ROI Potential 02/26/2020 08:58:36 AM
AMRN News: Amarin to Present at Two Upcoming Investor Conferences 02/20/2020 06:00:10 AM
AMRN News: Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020 02/19/2020 04:15:10 PM
AMRN News: Amended Statement of Ownership (sc 13g/a) 02/14/2020 04:25:35 PM
AMRN News: Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval 02/06/2020 09:26:23 PM
PostSubject
#259977  Sticky Note Jefferies Conference call from this morning labner 04/01/20 07:36:35 PM
#253398  Sticky Note https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154038753[/u HDGabor 03/18/20 11:05:45 AM
#195491  Sticky Note It's actually pretty simple. I have been KCSVEN 06/06/19 11:31:13 AM
#261355   Mochida did that with Epadel (very similar to garynavarre 04/03/20 02:02:15 PM
#261354   I just realized I'm in a binary response mode. shadolane 04/03/20 02:02:09 PM
#261353   Please send this to Elisabeth (IR) for Amarin concapk 04/03/20 02:02:01 PM
#261352   c- The court then found that, during prosecution, HDGabor 04/03/20 02:01:45 PM
#261351   This could be a tactic being discussed or rtc110 04/03/20 02:00:42 PM
#261350   Hikma to "at risk launch" the generic swg_tdr 04/03/20 02:00:21 PM
#261349   MEDACorp Lawyer Suggests Low Likelihood of AMRN Win beachboat983 04/03/20 01:57:42 PM
#261348   Interesting read, esp the follow, quote: Question: The USPTO circuitcity 04/03/20 01:57:30 PM
#261347   Probably the best path, but could they just Pittkid 04/03/20 01:54:56 PM
#261346   Then why are no other patent lawyers talking beachboat983 04/03/20 01:54:41 PM
#261345   patents are gone; covid could delay appeal a daveymoore 04/03/20 01:54:13 PM
#261344   But weren't their patents invalidated...? Or do you beachboat983 04/03/20 01:52:06 PM
#261343   Excellent read. Thank you. Restingzebra 04/03/20 01:51:29 PM
#261342   Mitra, Was this sent to IR in case it amarininvestor 04/03/20 01:49:18 PM
#261341   Nothing makes sense about AMRN'S path for quite shadolane 04/03/20 01:48:47 PM
#261340   Seems like her honor is applying double standards. Restingzebra 04/03/20 01:47:38 PM
#261339   Major break through if someone can get his jomama9231 04/03/20 01:47:24 PM
#261338   HDG- Good point, but what I mean is beachboat983 04/03/20 01:45:17 PM
#261337   And Du said herself in her obviousness logic TastyTheElf 04/03/20 01:45:06 PM
#261336   Captn ..i had the same thoughts...if you look biowreck 04/03/20 01:43:26 PM
#261335   you might be able to get your money daveymoore 04/03/20 01:40:43 PM
#261334   Give the pharmacists $10 for each Vascepa RX Sluicebox 04/03/20 01:36:16 PM
#261333   Feels like "cite" and "consider" are two different things. TastyTheElf 04/03/20 01:35:10 PM
#261332   No chance, but Monday I would take $15 invest2992 04/03/20 01:29:43 PM
#261331   Interesting that Du failed to find a nexus Restingzebra 04/03/20 01:26:53 PM
#261330   HDG, I would imagine, you would appreciate the ilovetech 04/03/20 01:23:35 PM
#261329   Guess we have argue both side of ex. Appeal circuitcity 04/03/20 01:23:10 PM
#261328   Anxiously waiting, but take your time, appeciate the circuitcity 04/03/20 01:22:01 PM
#261327   Re patents: Do any of AMRN's patents regarding Greymatter1 04/03/20 01:20:34 PM
#261326   all retail selling lol; i see no shorting daveymoore 04/03/20 01:19:09 PM
#261325   If the only difference between Vascepa and Generic Greymatter1 04/03/20 01:17:35 PM
#261324   I have very close experience before like: This around: circuitcity 04/03/20 01:16:54 PM
#261323   General Question for the board:Back before the REDUCE-IT CaptBeer 04/03/20 01:14:43 PM
#261322   Question by dazed investor..me flubber 04/03/20 01:12:15 PM
#261321   Pittkid, That would only harm Vascepa as insurance couldbebetter 04/03/20 01:11:41 PM
#261320   settlement is a joke; the whole world can daveymoore 04/03/20 01:11:04 PM
#261319   and yet another fraud action daveymoore 04/03/20 01:10:29 PM
#261318   j- Thx. Doc 331 Kurabayashi was considered by the United HDGabor 04/03/20 01:10:07 PM
#261317   Deal with whom? rtc110 04/03/20 01:09:20 PM
#261316   Yes, settlement can be path towards rebound, but marjac 04/03/20 01:07:20 PM
#261315   Raf, JL had a post earlier this morning Invest83838 04/03/20 01:06:22 PM
#261314   HDG: if AMRN's margins are 70-80% and generics Greymatter1 04/03/20 01:06:00 PM
#261313   Agree Bidmark Invest83838 04/03/20 01:05:18 PM
#261312   So base on yr comment, settle is still circuitcity 04/03/20 01:03:38 PM
#261311   Agreed. Why ask for an expedited review? The Greymatter1 04/03/20 01:02:55 PM
#261310   the ex-bear convicted sex offender you mean.... louieblouie 04/03/20 01:00:44 PM
#261309   as appeal drags on what will stock do? daveymoore 04/03/20 01:00:29 PM
#261308   CC,....greed postes 04/03/20 12:59:51 PM
#261307   You want BOD gone but bought more shares...is mc73 04/03/20 12:59:46 PM
#261306   But any idea/guessing why mgmt not interested at circuitcity 04/03/20 12:55:44 PM
PostSubject